PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 5 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Macrocyclic ellagitannins (cuphiin D1, D2, oenothein B, and woodfordin C) significantly inhibited the growth of KB, HeLa, DU-145, Hep 3B, and HL-60 cell lines, and inhibited S-180 tumor cells in mice [PMID:10403559].
Cuphiin D1 induced cytotoxicity (IC50 = 16 microM) and apoptosis in HL-60 cells [PMID:10737711].
Cuphiin D1 inhibited HeLa cell growth (IC50 = 14.2 micrograms/ml at 48h) with higher selectivity for tumor cells over normal cervical fibroblasts [PMID:12529981].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 10737711 (2000) — Cuphiin D1, the macrocyclic hydrolyzable tannin induced apoptosis in HL-60 cell line. · Cancer letters
- 2.PMID: 10403559 (1999) — Antitumor activity of four macrocyclic ellagitannins from Cuphea hyssopifolia. · Cancer letters
- 3.PMID: 33953638 (2021) — New records in vascular plants alien to Tenerife (Spain, Canary Islands). · Biodiversity data journal
- 4.PMID: 12553063 (2002) — In vitro immunomodulatory effects of cuphiin D1 on human mononuclear cells. · Anticancer research
- 5.PMID: 12529981 (2002) — Cytotoxic effects of cuphiin D1 on the growth of human cervical carcinoma and normal cells.